TO THE Manager- Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: TO THE Manager- Pharmaceutical Import Records from India — 4 Products, $94.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO THE Manager- — Pharmaceutical Importer Profile (2026) | 4 Products, $94.6K Trade | TransData Nexus

TO THE Manager-

Pharmaceutical Importer · Brazil · Advanced Diabetes Medications Focus · $94.6K Total Trade · DGFT Verified

TO THE Manager- is a pharmaceutical importer based in Brazil with a total trade value of $94.6K across 4 products in 2 therapeutic categories. Based on 38 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. TO THE Manager- sources from 45 verified Indian suppliers, with Gmsanjivani Llp accounting for 32.3% of imports.

TO THE Manager- — Import Portfolio & Supplier Network

TO THE Manager- import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO THE Manager-?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gmsanjivani Llp	$2.7M	2,559	32.3%
Healing Pharma India Private Limited	$840.7K	699	10.1%
Accelius Global	$745.9K	107	9.0%

What Formulations Does TO THE Manager- Import?

Formulation	Value	Ships
Modalert 200MG (modafinil)	$191.2K	18
We intend to claim rewards under rodtepscheme" rabio (rabies vaccine	$126.1K	4
We intend to claim rewards under rodtepschemerabio (rabies vaccine)	$124.6K	5
Iohexol injection USP 350 mgl/ML -100 ML	$117.0K	3
(pharmaceuticals product & medicine	$94.2K	162
Varenismart 1 (varenicline tartrate 1MG)	$70.9K	3
Harmless medicine for human	$64.1K	79
We intend to claim rewards under	$61.3K	88
Sodium chloride intravenous infusion	$60.9K	3
Varenismart 1 (varenicline tartrate 1MG)(1x10 tabs	$60.3K	2
Sevoflurane 250ML	$58.4K	2
Ayurvedic and herbal products for	$53.7K	108
Tenof 300MG	$52.2K	2
Cefixime 400 MG tablet (10 x 10 tabs)	$50.0K	1
Pharmaceutical finished formulation	$43.0K	3

TO THE Manager- imports 5,721 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Semaglutide	Advanced Diabetes Medications	$69.9K	24	1.4%	14
2	Tofacitinib	Advanced Oncology	$13.3K	7	0.3%	11
3	Actinomycin	Advanced Oncology	$8.1K	2	0.3%	8
4	Chlorambucil	Advanced Oncology	$3.2K	5	0.9%	10

TO THE Manager- imports 4 pharmaceutical products across 2 categories into Brazil totaling $94.6K.

TO THE Manager- — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO THE Manager- is a pharmaceutical importer and buyer based in Brazil, specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. The company plays a pivotal role in Brazil's pharmaceutical distribution network by sourcing a diverse range of medications to meet the country's healthcare needs. With a total import value of $95,000 USD over 38 shipments from India between 2022 and 2026, TO THE Manager- demonstrates a consistent engagement in the international pharmaceutical trade.

The company's portfolio is concentrated in two therapeutic categories: Advanced Diabetes Medications and Advanced Oncology, reflecting a strategic focus on high-demand areas within Brazil's healthcare sector. Notably, the top five imported products—Semaglutide, Tofacitinib, Actinomycin, and Chlorambucil—account for 100% of the company's imports, indicating a highly specialized sourcing strategy. This concentration suggests that TO THE Manager- may serve as a primary wholesaler or distributor, facilitating the availability of these critical medications across Brazil.

2Distribution Network

While specific details about TO THE Manager-'s warehouse locations and logistics capabilities are not publicly available, the company's import activities indicate a well-established distribution network within Brazil. The consistent importation of pharmaceutical products from India over a four-year period suggests efficient logistics and warehousing operations capable of handling international shipments. Given the therapeutic focus on diabetes and oncology medications, it is likely that TO THE Manager- collaborates with hospitals, clinics, and pharmacies nationwide to ensure the timely delivery of these essential drugs.

3Industry Role

TO THE Manager- occupies a significant position in Brazil's pharmaceutical supply chain, likely functioning as a primary wholesaler or distributor. The company's specialized focus on high-demand therapeutic areas, such as Advanced Diabetes Medications and Advanced Oncology, positions it as a key player in ensuring the availability of critical medications. By importing finished pharmaceutical formulations from India, TO THE Manager- contributes to the diversification and stability of Brazil's pharmaceutical market, catering to the specific needs of healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO THE Manager-

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The sourcing strategy of TO THE Manager- exhibits a high degree of concentration, with the top five imported products accounting for 100% of the company's imports. This indicates a deliberate focus on a narrow range of medications, which could be a strategic choice to specialize in high-demand therapeutic areas. However, such concentration also presents potential risks, including supply chain disruptions or regulatory changes affecting these specific products. The company's reliance on a single source for these medications may expose it to vulnerabilities if any issues arise with the supplier or the products themselves.

2Supply Chain Resilience

TO THE Manager-'s supply chain resilience appears to be robust, given the consistent importation of pharmaceutical products from India over a four-year period. The company's engagement with multiple Indian suppliers, including GMSANJIVANI LLP, HEALING PHARMA INDIA PRIVATE LIMITED, and ACCELIUS GLOBAL, suggests a diversified sourcing strategy that can mitigate risks associated with single-source dependency. Additionally, the importation of 5,721 unique pharmaceutical formulations indicates a broad product base, which can enhance supply chain flexibility. However, the company's focus on specific therapeutic areas may limit its ability to adapt to sudden shifts in market demand or regulatory changes affecting these categories.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the regulation of pharmaceutical products is overseen by the Agência Nacional de Vigilância Sanitária (ANVISA), the Brazilian Health Regulatory Agency. ANVISA is responsible for ensuring the safety, efficacy, and quality of health-related products, including drugs and biological products. The agency's regulatory framework encompasses the authorization of clinical trials, marketing authorizations for drugs, and post-marketing surveillance. For foreign companies, including Indian exporters, it is mandatory to designate a legally established partner in Brazil to handle administrative procedures for obtaining pre-market approvals with ANVISA. This partner assumes legal responsibility for the products imported and distributed within Brazilian territory. (gov.br)

2Import Licensing & GMP

Importing pharmaceutical products into Brazil requires compliance with ANVISA's regulations, including obtaining the necessary import licenses and ensuring that products meet Good Manufacturing Practices (GMP). ANVISA's Resolution RDC 658/2022 outlines the general GMP guidelines for medicines, aligning with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards. Foreign companies must collaborate with a local partner in Brazil to navigate the import licensing process and ensure that their products adhere to ANVISA's GMP requirements. This partnership is essential for the successful importation and commercialization of pharmaceutical products in the Brazilian market. (gov.br)

TO THE Manager- — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO THE Manager-'s focus on Advanced Diabetes Medications and Advanced Oncology reflects a strategic alignment with Brazil's healthcare priorities. The high prevalence of diabetes and cancer in the country drives significant demand for effective treatments in these therapeutic areas. By specializing in these categories, TO THE Manager- positions itself to meet critical healthcare needs, ensuring the availability of essential medications for patients and healthcare providers. This targeted approach also allows the company to build expertise and strong relationships within these niches, enhancing its competitive position in the Brazilian pharmaceutical market.

2Sourcing Profile

TO THE Manager- employs a sourcing strategy that focuses on finished pharmaceutical formulations, particularly from India. This approach allows the company to leverage India's robust pharmaceutical manufacturing capabilities and cost advantages. By importing finished products, TO THE Manager- can offer a diverse range of medications without the complexities associated with manufacturing. This strategy aligns with the company's focus on high-demand therapeutic areas, ensuring a steady supply of essential drugs to the Brazilian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to TO THE Manager-

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with TO THE Manager-. The company's focus on Advanced Diabetes Medications and Advanced Oncology presents a niche market where specialized products are in demand. Indian exporters with expertise in these therapeutic areas can align their offerings with TO THE Manager-'s needs, potentially leading to a fruitful partnership. However, new suppliers should be prepared to meet ANVISA's regulatory requirements, including GMP compliance and product registration, to successfully enter the Brazilian market.

2Requirements & Qualifications

Indian exporters seeking to supply TO THE Manager- and enter the Brazilian market must ensure that their products comply with ANVISA's regulations. This includes obtaining the necessary import licenses, ensuring Good Manufacturing Practices (GMP) compliance, and registering products with ANVISA. Additionally, labeling must be in Portuguese and meet ANVISA's standards. Collaboration with a local partner in Brazil is essential to navigate the regulatory landscape and facilitate the importation process. (gov.br)

3How to Approach

Frequently Asked Questions — TO THE Manager-

What products does TO THE Manager- import from India?

TO THE Manager- imports 4 pharmaceutical products across 2 categories. Top imports: Semaglutide ($69.9K), Tofacitinib ($13.3K), Actinomycin ($8.1K), Chlorambucil ($3.2K).

Who supplies pharmaceuticals to TO THE Manager- from India?

TO THE Manager- sources from 45 verified Indian suppliers. The primary supplier is Gmsanjivani Llp (32.3% of imports, $2.7M).

What is TO THE Manager-'s total pharmaceutical import value?

TO THE Manager-'s total pharmaceutical import value from India is $94.6K, based on 38 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO THE Manager- focus on?

TO THE Manager- imports across 2 categories. The largest: Advanced Diabetes Medications (73.9%), Advanced Oncology (26.1%).

Get Full TO THE Manager- Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.